Biotech Startups
9,603 companies tagged Biotech, with their investors and founders.
Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
3 investors
The page suggests a life sciences focus on single-cell analysis and disease research, but provides no concrete details about the product or services offered.
3 investors
argenx is an immunology company that operates an antibody innovation ecosystem where scientists and antibody engineers develop novel targets, disease pathways, and therapeutic antibodies. It builds a proprietary portfolio of first-in-class product candidates, engineered with academic partners, to translate immunology research into medicines for patients.
3 investors
Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease. It focuses on autoimmune neuropsychiatry, addressing conditions including encephalitis, schizophrenia, dementia, and cancer-related cognitive impairment.
3 investors
Artos provides AI-powered software tools for Chemistry, Manufacturing, and Controls (CMC) teams in the pharmaceutical industry to draft, manage, and quality-check regulatory documentation. The platform uses specialized AI systems designed to handle dense tabular data and non-standard formats common in regulatory Module 3 documents.
3 investors
Aruna Bio develops a proprietary neural exosome platform and a lead therapeutic neural cell-derived exosome, AB126, designed to cross the blood-brain barrier. The company targets acute neurological conditions and chronic neurodegenerative diseases through mechanisms that reduce neuro-inflammation and promote neuro-protection and neuro-regeneration.
3 investors
Arzeda designs proteins and metabolic pathways using computational tools, including its Archytas protein design software and Scylax metabolic pathway design software. The company operates in the computational biology and protein engineering field.
3 investors
Asgard Therapeutics is a biotech company developing cancer immunotherapies using direct cell reprogramming and gene therapy, with a lead program (AT-108) built as an off-the-shelf gene therapy. Spun off from Lund University, it works in immuno-oncology.
3 investors
Aspect Analytics develops Weave, software that aligns and analyzes spatial and molecular data (spatial transcriptomics, proteomics, metabolomics, mass spectrometry imaging, and histology) at single-cell precision to study cellular neighborhoods and tissue architecture. It serves pharma companies, CROs, and research institutes to support drug discovery and development through reproducible, AI-ready spatial biology workflows.
3 investors
Astek Diagnostics develops a diagnostic platform for rapid and accurate detection of urinary tract infections and related conditions in clinical specimens. The company serves physicians and patients needing point-of-care diagnostic solutions for infectious diseases.
3 investors
ATAI is developing rapid-acting, durable mental health treatments to address unmet needs in psychiatric conditions affecting over one billion people globally. The company combines drug development, healthcare, and commercialization expertise to create evidence-based therapies for large-scale patient impact.
3 investors
ATB Therapeutics develops targeted antibody therapies, including its "atbody" format, for hematological malignancies, autoimmune diseases, and solid tumors. The company also operates a plant-based manufacturing technology platform for producing these therapeutics.
3 investors
Atlantic Fish produces cultivated seafood by growing fish from muscle cells, offering a domestically produced, contaminant-free alternative to wild-caught fish. The company aims to create a scalable and sustainable source of seafood.
3 investors
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages. The company operates in the biotech and drug development space targeting these progressive, often fatal diseases.
3 investors
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease. The company leverages a proprietary discovery platform targeting immune-mediated disorders in pulmonary and systemic conditions.
3 investors
3 investors
Autopoiesis builds AI systems capable of autonomous scientific discovery, operating Aristotle, an AI research partner that assists scientists with hypothesis formation, evidence evaluation, and research direction decisions.
3 investors
Avammune is a drug discovery company developing novel therapeutics for hard-to-treat solid tumors using computational chemistry, immunology, and targeted radiotherapeutics. The company focuses on converting immunologically cold tumors into responsive ones and identifying new cancer dependencies as therapeutic targets.
3 investors
Avicedar develops glyco-immune checkpoint therapeutics to treat immune-mediated diseases, with an initial focus on Macular Degeneration. The company operates in the biotechnology and drug development sector.
3 investors
Avivomed is a medical device company developing minimally invasive neuromodulation therapies for patients with obstructive sleep apnea. Based in the Minneapolis area, it targets mild-to-moderate OSA patients who cannot tolerate CPAP.
3 investors
Axol Bioscience manufactures human induced pluripotent stem cell (iPSC)-derived cells and provides laboratory services including iPSC banking, reprogramming, gene editing, and cell manufacturing for preclinical drug discovery and disease modeling. It serves pharmaceutical companies, CROs, biotech firms, and academic institutions across neuroscience, ophthalmology, dermatology, and cardiovascular research, shipping from US and European hubs.</parameter> <parameter name="founders">[]
3 investors
b12 develops AI agents and lab automation software to help chemists plan, optimize, and execute the synthesis of complex molecules. The platform combines chemistry expertise with agentic AI systems to streamline organic synthesis workflows.
3 investors
BACTA is an AI-powered bioproduction company that uses microorganisms to produce industrial ingredients such as astaxanthin for cosmetics, human nutrition, and animal nutrition markets.
3 investors
Bacto.bio is a biotechnology company developing a multidisciplinary pipeline, staffed by scientists, engineers, and other technical specialists.
3 investors